Skip to main content
SpringerLink
Log in

Combination disease-modifying drugs reduce costs in RA

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. British pounds

Reference

  • Scott DL et al. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ 2015: h1046, No. 350, 13 Mar 2015. Available from: URL: http://dx.doi.org/10.1136/bmj.h1046

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Combination disease-modifying drugs reduce costs in RA. PharmacoEcon Outcomes News 724, 6 (2015). https://doi.org/10.1007/s40274-015-1984-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-1984-2

Search

Navigation